Date: 30-Aug-2019

U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta

The U.S. Food and Drug Administration on Thursday granted Mylan NV tentative approval for its generic version of Eli Lilly and Cos lung cancer drug Alimta. Shares of Mylan closed up 3.9% at $19.90 on Thursday. A tentative approval generally signals that the FDA has signed off on the companys marketing application, but that it cannot sell the medicine until the U.S. patents have expired.